Terms: = Lung cancer AND STK11, LKB1, 6794, ENSG00000118046, Q15831, PJS AND Prognosis
71 results:
1. Effect of the stk11 mutation on therapeutic efficacy and prognosis in patients with non-small cell lung cancer: a comprehensive study based on meta-analyses and bioinformatics analyses.
Xu K; Lu W; Yu A; Wu H; He J
BMC Cancer; 2024 Apr; 24(1):491. PubMed ID: 38632512
[TBL] [Abstract] [Full Text] [Related]
2. Clinicopathologic features, concurrent genomic alterations, and clinical outcomes of patients with KRAS G12D mutations in resected lung adenocarcinoma.
Cao H; Ma Z; Huang Q; Han H; Li Y; Zhang Y; Chen H
Eur J Cancer; 2024 May; 202():113985. PubMed ID: 38452722
[TBL] [Abstract] [Full Text] [Related]
3. stk11/lkb1 alterations worsen the poor prognosis of KRAS mutated early-stage non-squamous non-small cell lung carcinoma, results based on the phase 2 IFCT TASTE trial.
Baptiste Oudart J; Garinet S; Leger C; Barlesi F; Mazières J; Jeannin G; Audigier-Valette C; Morot-Sibilot D; Langlais A; Amour E; Mathiot N; Birsen G; Blons H; Wislez M
Lung Cancer; 2024 Apr; 190():107508. PubMed ID: 38428265
[TBL] [Abstract] [Full Text] [Related]
4. [Cytopathological characteristics of SMARCA4-deficient thoracic undifferentiated tumors in serous effusion].
Wang WN; Liu XT; Liang YM
Zhonghua Bing Li Xue Za Zhi; 2024 Feb; 53(2):143-148. PubMed ID: 38281781
[No Abstract] [Full Text] [Related]
5. Josephin domain containing 2 (JOSD2) promotes lung cancer by inhibiting lkb1 (Liver kinase B1) activity.
Yuan T; Zeng C; Liu J; Zhao C; Ge F; Li Y; Qian M; Du J; Wang W; Li Y; Liu Y; Dai X; Zhou J; Chen X; Ma S; Zhu H; He Q; Yang B
Signal Transduct Target Ther; 2024 Jan; 9(1):11. PubMed ID: 38177135
[TBL] [Abstract] [Full Text] [Related]
6. Caloric restriction and metformin selectively improved lkb1-mutated NSCLC tumor response to chemo- and chemo-immunotherapy.
Ndembe G; Intini I; Moro M; Grasselli C; Panfili A; Panini N; Bleve A; Occhipinti M; Borzi C; Garassino MC; Marabese M; Canesi S; Scanziani E; Sozzi G; Broggini M; Ganzinelli M
J Exp Clin Cancer Res; 2024 Jan; 43(1):6. PubMed ID: 38163906
[TBL] [Abstract] [Full Text] [Related]
7. The prognostic impact of KRAS, TP53, stk11 and KEAP1 mutations and their influence on the NLR in NSCLC patients treated with immunotherapy.
Proulx-Rocray F; Routy B; Nassabein R; Belkaid W; Tran-Thanh D; Malo J; Tonneau M; Ouarzadi OE; Florescu M; Tehfe M; Blais N
Cancer Treat Res Commun; 2023; 37():100767. PubMed ID: 37832364
[TBL] [Abstract] [Full Text] [Related]
8. Clinical Characteristics and Responses to Immune Checkpoint Inhibitors in RET-Aberrant Digestive Tract Tumours.
Yen CC; Yeh YM; Huang HY; Ting YL; Fu PA; Lin TC; Liu IT; Yen CJ
Target Oncol; 2023 Jul; 18(4):611-623. PubMed ID: 37347391
[TBL] [Abstract] [Full Text] [Related]
9. Prognostic value of KRAS G12C mutation in lung adenocarcinoma stratified by stages and radiological features.
Cao H; Ma Z; Li Y; Zhang Y; Chen H
J Thorac Cardiovasc Surg; 2023 Dec; 166(6):e479-e499. PubMed ID: 37142051
[TBL] [Abstract] [Full Text] [Related]
10. Machine learning-based immune phenotypes correlate with stk11/KEAP1 co-mutations and prognosis in resectable NSCLC: a sub-study of the TNM-I trial.
Rakaee M; Andersen S; Giannikou K; Paulsen EE; Kilvaer TK; Busund LR; Berg T; Richardsen E; Lombardi AP; Adib E; Pedersen MI; Tafavvoghi M; Wahl SGF; Petersen RH; Bondgaard AL; Yde CW; Baudet C; Licht P; Lund-Iversen M; Grønberg BH; Fjellbirkeland L; Helland Å; Pøhl M; Kwiatkowski DJ; Donnem T
Ann Oncol; 2023 Jul; 34(7):578-588. PubMed ID: 37100205
[TBL] [Abstract] [Full Text] [Related]
11. Long-Term Outcomes and Molecular Correlates of Sotorasib Efficacy in Patients With Pretreated
Dy GK; Govindan R; Velcheti V; Falchook GS; Italiano A; Wolf J; Sacher AG; Takahashi T; Ramalingam SS; Dooms C; Kim DW; Addeo A; Desai J; Schuler M; Tomasini P; Hong DS; Lito P; Tran Q; Jones S; Anderson A; Hindoyan A; Snyder W; Skoulidis F; Li BT
J Clin Oncol; 2023 Jun; 41(18):3311-3317. PubMed ID: 37098232
[No Abstract] [Full Text] [Related]
12. Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without stk11 and/or KEAP1 mutations in a real-world setting.
Julian C; Pal N; Gershon A; Evangelista M; Purkey H; Lambert P; Shi Z; Zhang Q
BMC Cancer; 2023 Apr; 23(1):352. PubMed ID: 37069542
[TBL] [Abstract] [Full Text] [Related]
13. Histone Deacetylase 6 Inhibition Exploits Selective Metabolic Vulnerabilities in lkb1 Mutant, KRAS Driven NSCLC.
Zhang H; Nabel CS; Li D; O'Connor RÍ; Crosby CR; Chang SM; Hao Y; Stanley R; Sahu S; Levin DS; Chen T; Tang S; Huang HY; Meynardie M; Stephens J; Sherman F; Chafitz A; Costelloe N; Rodrigues DA; Fogarty H; Kiernan MG; Cronin F; Papadopoulos E; Ploszaj M; Weerasekara V; Deng J; Kiely P; Bardeesy N; Vander Heiden MG; Chonghaile TN; Dowling CM; Wong KK
J Thorac Oncol; 2023 Jul; 18(7):882-895. PubMed ID: 36958689
[TBL] [Abstract] [Full Text] [Related]
14. A subset of VEGFR-TKIs activates AMPK in lkb1-mutant lung cancer.
Yang L; Zhang Q; Xiong Y; Dang Z; Xiao H; Chen Q; Dai X; Zhang L; Zhu J; Wang D; Li M
Cancer Sci; 2023 Apr; 114(4):1651-1662. PubMed ID: 36459496
[TBL] [Abstract] [Full Text] [Related]
15. RNF126 contributes to stem cell-like properties and metastasis in hepatocellular carcinoma through ubiquitination and degradation of lkb1.
Huang J; Li Y; Zheng M; He H; Xu D; Tian D
Hum Cell; 2022 Nov; 35(6):1869-1884. PubMed ID: 36068398
[TBL] [Abstract] [Full Text] [Related]
16. Clinical impact of stk11 mutation in advanced-stage non-small cell lung cancer.
Rosellini P; Amintas S; Caumont C; Veillon R; Galland-Girodet S; Cuguillière A; Nguyen L; Domblides C; Gouverneur A; Merlio JP; Bezin J; Girodet PO
Eur J Cancer; 2022 Sep; 172():85-95. PubMed ID: 35759814
[TBL] [Abstract] [Full Text] [Related]
17. Deciphering the tumor microenvironment cell-infiltrating landscape reveals microenvironment subtypes and therapeutic potentials for nonsquamous NSCLC.
Chen H; Zhang T; Zhang Y; Wu H; Fang Z; Liu Y; Chen Y; Wang Z; Jia S; Ji X; Shang L; Du F; Liu J; Lu M; Chong W
JCI Insight; 2022 Jun; 7(12):. PubMed ID: 35511432
[TBL] [Abstract] [Full Text] [Related]
18. PPDPF Promotes the Progression and acts as an Antiapoptotic Protein in Non-Small Cell lung cancer.
Yun M; Yingzi L; Jie G; Guanxin L; Zimei Z; Zhen C; Zhi L; Yingjie N; Lunquan S; Tao C; Yuezhen D; Chengzhi Z
Int J Biol Sci; 2022; 18(1):214-228. PubMed ID: 34975328
[TBL] [Abstract] [Full Text] [Related]
19. Clinicopathological features and genomic profiles of hepatoid adenocarcinoma of the lung: Report of four cases.
Sun H; Li X; Zhang J; Liu Y
Pathol Res Pract; 2022 Jan; 229():153652. PubMed ID: 34826742
[TBL] [Abstract] [Full Text] [Related]
20. lkb1 expression and the prognosis of lung cancer: A meta-analysis.
Lin C; Lin X; Lin K; Tan J; Wei C; Liu T
Medicine (Baltimore); 2021 Nov; 100(46):e27841. PubMed ID: 34797317
[TBL] [Abstract] [Full Text] [Related]
[Next]